

Integrated Peptide Discovery to Manufacturing

Sai Life Sciences offers a comprehensive, end-to-end peptide capability spanning discovery, development, and manufacturing. We bring deep expertise across diverse peptide modalities—delivering fully integrated programs that combine chemistry, biology, scale-up, and impurity synthesis under one roof.

Discovery Excellence

Our peptide discovery group provides a fully integrated drug discovery service, seamlessly combining:

- Design and synthesis of active complex peptides
- Biology integration and screening support
- Impurity synthesis and analytical characterization
- Process development and early scale-up

We leverage state-of-the-art technologies, including automated solid-phase peptide synthesis (SPPS), advanced isolation techniques, and high-resolution purification platforms to ensure speed, quality, and reproducibility.

Our expertise spans a wide spectrum of peptide types

- Linear peptides
- Macrocyclic peptides
- Constrained peptides
- Disulfide-bridged peptides
- Bi- and tricyclic peptides
- Peptide–drug conjugates (PDCs)
- Oligopeptides and complex conjugates

We routinely deliver focused and diverse peptide libraries tailored to target biology, producing material at scales ranging from milligrams to tens of grams.

Advancing CMC Capabilities

Sai Life Sciences is actively expanding its peptide CMC infrastructure to support seamless progression from discovery into development.

- Proven experience in **liquid-phase synthesis of short peptides**, delivered at scales exceeding 100 kg
- Ongoing investment in a **Centre of Excellence for Peptide Research & Development** at our Hyderabad campus

The upcoming Centre of Excellence (operational Q1 2027) will integrate cutting-edge peptide technologies to support:

- Process development and optimization
- Non-GMP batch production in the hundreds-of-grams scale
- Robust analytical and characterization workflows

GMP Manufacturing for Peptides

To complete our end-to-end offering, Sai Life Sciences plans to establish a dedicated **GMP peptide manufacturing unit** at our new Choutuppal site.

This facility will:

- Incorporate both solid- and liquid-phase manufacturing technologies
- Support peptide production at multiple tens-of-kilogram scale
- Enable scalable, regulatory-ready supply

The GMP unit is targeted to be operational by the end of 2027, strengthening our ability to support clients from early discovery through clinical and commercial supply.

Why Partner with Sai Life Sciences for Peptides?

- Fully integrated discovery-to-development platform
- Broad modality expertise across complex peptide architectures
- Flexible scale—from milligram libraries to multi-kilogram manufacturing
- Strategic investments in next-generation peptide R&D and GMP infrastructure

Our expanding peptide capabilities position us as a long-term partner for innovators advancing peptide therapeutics—from concept to clinic and beyond.